Notes on building a laboratory company
A laboratory is not an exciting business, and I have come to think that is its principal virtue. From inside Veltrion, the days are made of accreditation audits, reagent procurement, instrument calibration, sample logistics and the slow accumulation of clinician trust. None of it photographs well. None of it produces the kind of story that gets told at conferences. But the same qualities that make a laboratory company dull to describe are the ones that make it hard to dislodge, and in African healthcare, defensibility is rarer and more valuable than novelty.
The moat is the boredom
There is a pattern I keep noticing. The healthcare businesses that attract the most attention, the apps, the platforms, the asset-light marketplaces, are also the easiest to copy. Their defensibility usually rests on being first, on a brand, or on capital outrunning a competitor. The businesses that attract the least attention, the ones knee-deep in regulation and physical infrastructure, are the hardest to copy, because the difficulty is the product.
A diagnostic laboratory cannot be spun up over a weekend. It needs accreditation, and accreditation is a process measured in months and years, not the launch of a website. It needs instruments that are expensive and slow to commission, a quality management system that survives audit, and staff with credentials that take years to earn and are scarce in most of the markets we operate in. It needs a referral base of clinicians who will only send samples once they trust the results, and trust in diagnostics is earned one accurate report at a time and lost with a single bad one.
Every one of those is a barrier to entry, and every one of them is boring. That is not a coincidence. Moats in healthcare are mostly made of accumulated, regulated, hard-to-rush effort. A competitor with more money than us cannot buy their way past an accreditation timeline or manufacture clinician trust with a marketing budget. They have to do the same slow work we did, while we are already doing it, ahead of them. The boredom compounds in our favour.
Infrastructure is sticky in ways software is not
Software defensibility decays. Features get copied, switching costs erode, a better-funded entrant rewrites the category. Physical infrastructure behaves differently. Once a laboratory is embedded in a regional care pathway, once hospitals route their samples to it, once the logistics for transporting specimens are tuned to it, the cost of ripping it out and replacing it is high for everyone involved. Stickiness is not a feature you build; it is a position you occupy.
That stickiness is amplified by the conditions of the markets we serve. Cold chain is genuinely hard here. Moving a temperature-sensitive sample from a clinic in one region to a testing facility in another, intact and within its viable window, across roads and borders and power interruptions, is an operational problem that defeats most newcomers. We have spent years solving it, and the solution is not a piece of intellectual property anyone can read and replicate. It is a network, a set of relationships, a fleet of habits. The same is true of reagent supply in markets where importation is slow and currencies move against you. Holding the right inventory, hedged sensibly, sourced through relationships that survive a shortage, is unglamorous logistics that quietly determines whether you can deliver a result on Tuesday or next month.
There is a macro tailwind worth naming. Decentralised clinical trials are pushing testing capacity closer to patients, and African populations are increasingly relevant to global drug development. Regional regulatory harmonisation, the African Medicines Agency among other efforts, is slowly raising the value of being an accredited, trusted laboratory partner that international sponsors can actually use. The infrastructure we are building for a domestic diagnostic business turns out to be the same infrastructure a trial sponsor needs. That optionality came free with the boring core.
What the field notes actually teach
If I were to compress what building Veltrion has taught me, it would be this. The temptation in any frontier market is to chase the asset-light, fast-scaling story, because capital rewards the narrative and infrastructure looks like a trap, slow and heavy and unforgiving. But the asset-light story is asset-light for everyone, including the next entrant, which means it defends nothing. The heavy, regulated, physical business is a trap only for the people who lack the patience to build it. For the ones who do, the heaviness becomes the wall.
The work does not get easier. Accreditation must be maintained, not just won. Quality is a daily discipline, not a milestone. Trust, once earned, is rented rather than owned, and a single systemic error can return you to the start. None of that is a reason to avoid the business. It is the reason the business is worth building, because every one of those ongoing difficulties is also an ongoing barrier to whoever might want to take your place.
I will take the unglamorous, infrastructure-heavy, regulation-bound bet over the elegant one most days. Not because I am drawn to difficulty for its own sake, but because in African healthcare the difficult things are the durable things. The market does not reward you quickly for building them. It rewards you slowly, and then it keeps rewarding you, which is the only kind of return that compounds.
